Delta variant outbreaks in the US affect Össur sales

The negative developments in Q3 have caused Össur to downgrade its full year guidance to the lower boundary of its previous guidance interval.

By Marketwire, TRANSLATED by DANIEL PEDERSEN

Published: 26.10.21 at 10:45

The Covid-19 pandemic, and in particular, the outbreaks of the highly contagious Delta variant, is affecting sales at medtech company Össur.

Sales in the company's biggest market, the US and other parts of America, have been particularly affected, Össur reports in connection with the release of its third quarterly report of the year.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.